Publications (33) MÓNICA ANDREA MUSTEANU publications

2024

  1. CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis

    Cancer Letters, Vol. 588

  2. Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 121, Núm. 36

2023

  1. Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 120, Núm. 9

  2. Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas

    The Journal of clinical investigation, Vol. 133, Núm. 7

  3. Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity

    Cell, Vol. 186, Núm. 12, pp. 2628-2643.e21

2022

  1. KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors

    Molecular Oncology, Vol. 16, Núm. 17, pp. 3066-3081

  2. Structure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation

    Molecular Cell, Vol. 82, Núm. 18, pp. 3438-3452.e8

  3. The RAF/MEK clamp VS-6766 shows strong anti-tumor activity across multiple MAPK pathway alterations, with a preferential effect on KRAS G12V

    European Journal of Cancer, Vol. 174, pp. S18

2021

  1. ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung cancer

    Molecular Cancer Therapeutics, Vol. 20, Núm. 4, pp. 641-654

  2. KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 30

  3. RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression

    Cancer Cell

2020

  1. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 117, Núm. 39, pp. 24415-24426

2019

  1. A mouse model to assess STAT3 and STAT5A/B combined inhibition in health and disease conditions

    Cancers, Vol. 11, Núm. 9

  2. Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF

    Cancer Cell, Vol. 35, Núm. 4, pp. 573-587.e6

  3. Effects of a Ketogenic Diet on [18F]FDG-PET Imaging in a Mouse Model of Lung Cancer

    Molecular Imaging and Biology, Vol. 21, Núm. 2, pp. 279-285

2018

  1. Afatinib restrains K-RAS-driven lung tumorigenesis

    Science Translational Medicine, Vol. 10, Núm. 44

  2. c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling

    Cancer Cell, Vol. 33, Núm. 2, pp. 217-228.e4

2015

  1. Myeloid STAT3 promotes formation of colitisassociated colorectal cancer in mice

    OncoImmunology, Vol. 4, Núm. 4

  2. SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial

    Clinical Cancer Research, Vol. 21, Núm. 21, pp. 4811-4818

  3. Whole exome sequencing of rapid autopsy tumors and xenograft models reveals possible driver mutations underlying tumor progression

    PLoS ONE, Vol. 10, Núm. 11